Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate AN2 Therapeutics, Inc. before investing.

In this article, we go over a few key elements for understanding AN2 Therapeutics, Inc.’s stock price such as:

• AN2 Therapeutics, Inc.’s current stock price and volume
• Why AN2 Therapeutics, Inc.’s stock price changed recently
• Upgrades and downgrades for ANTX from analysts
• ANTX’s stock price momentum as measured by its relative strength

About AN2 Therapeutics, Inc. (ANTX)

Before we jump into AN2 Therapeutics, Inc.’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

AN2 Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics. The company’s initial candidate includes epetraborole, which is phase 3 clinical trial as a once-daily oral treatment for patients with non-tuberculous mycobacterial lung disease, as well as studying for the treatment of acute melioidosis. It also develops AN2-502998 (AN15368), an investigational, boron-based small molecule in development for the treatment of chronic Chagas disease that is in preclinical trials; and has various research programs targeting the development of novel compounds in oncology and infectious disease based on its boron chemistry platform. It has a license agreement with Anacor Pharmaceuticals, Inc. to use, develop, manufacture, commercialize compounds and products, including epetraborole for the treatment, diagnosis, or prevention of various human diseases; and Brii Biosciences Limited to research, develop, manufacture, and commercialize compounds and products comprising epetraborole in China, Hong Kong, Taiwan, and Macau for the diagnosis, treatment, and prevention of human diseases; and GSK plc for the development of new therapies for TB. AN2 Therapeutics, Inc. was incorporated in 2017 and is headquartered in Menlo Park, California.

Want to learn more about AN2 Therapeutics, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about AN2 Therapeutics, Inc..

AN2 Therapeutics, Inc.’s Stock Price as of Market Close

As of March 24, 2026, 4:00 PM, CST, AN2 Therapeutics, Inc.’s stock price was $3.770.

AN2 Therapeutics, Inc. is down 1.57% from its previous closing price of $3.830.

During the last market session, AN2 Therapeutics, Inc.’s stock traded between $3.440 and $3.820. Currently, there are approximately 30.36 million shares outstanding for AN2 Therapeutics, Inc..

AN2 Therapeutics, Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

AN2 Therapeutics, Inc. Stock Price History

AN2 Therapeutics, Inc.’s (ANTX) price is currently up 242.73% so far this month.

During the month of March, AN2 Therapeutics, Inc.’s stock price has reached a high of $6.910 and a low of $1.055.

Over the last year, AN2 Therapeutics, Inc. has hit prices as high as $6.910 and as low as $1.000. Year to date, AN2 Therapeutics, Inc.’s stock is up 230.7%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused AN2 Therapeutics, Inc. Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of March 24, 2026, there were 0 analysts who downgraded AN2 Therapeutics, Inc.’s stock and 1 analyst who upgraded over the last month.

Additionally, you'll want to evaluate AN2 Therapeutics, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on AN2 Therapeutics, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about AN2 Therapeutics, Inc. (ANTX) by visiting AAII Stock Evaluator.

Relative Price Strength of AN2 Therapeutics, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of March 24, 2026, AN2 Therapeutics, Inc. has a weighted four-quarter relative price strength of 94.45%, which translates to a Momentum Score of 99 and is considered to be Very Strong.

Want to learn more about how AN2 Therapeutics, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

AN2 Therapeutics, Inc. Stock Price: Bottom Line

As of March 24, 2026, AN2 Therapeutics, Inc.’s stock price is $3.770, which is down 1.57% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like AN2 Therapeutics, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.